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ABSTRACT
Objectives: Crohn’s disease (CD) is a repeating bowel disease characterized by remission and exacerbation periods.  
The disease mostly affects adults of reproductive age. Women with desires to conceive are concerned about the effects 
of CD on their fertility. To demonstrate the relationship between ovarian reserve and CD anti-Müllerian hormone (AMH) 
levels, antral follicle count (AFC) and ovarian volüme were evaluated.
Material and methods: The prospective case-controlled study was conducted at a tertiary referral center in Istanbul 
between March–August 2019. Ovarian functions were evaluated in 50 patients with CD and in 95 healthy women. Serum 
gonadotropin and AMH levels were determined. AFCs and ovarian volumes were calculated for all subjects. 
Results: AMH levels were significantly lower in CD patients (2.1 ± 0.8) compared to the control group (3.3 ± 0.9) (P = 0.001). 
Serum AMH levels were significantly lower in patients with active CD (2.1 ± 0.6) than the CD patients in remission (2.6 ± 0.8) 
(p = 0.002). Ovarian volumes and AFC values were significantly lower in both ovaries in CD patients compared to the 
controls (p < 0.05).
Conclusions: AMH levels, ovarian volume and AFC counts, and thus ovarian reserve was shown to be decreased in CD 
patients of reproductive age compared to healthy control subjects. Because possible effects of inflammatory damage 
may be seen in newly diagnosed female CD patients who desire to have a child, we believe that CD patients should be 
comprehensively assessed for ovarian reserve.
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INTRODUCTION 
Crohn’s disease (CD) is a repeating bowel disease 
characterized by remission and exacerbation periods [1]. 
The disease mostly affects adults of reproductive age. 
Young women with desire of conception usually are con-
cerned about the potential effects of CD on fertility and 
pregnancy [2].
According to the latest consensus of the Euro-
pean Crohn’s and Colitis Organisation (ECCO), a decrease 
in fertility is seen especially in women with active CD [3]. 
CD may reduce fertility directly through inflammation ob-
served in the fallopian tubes and in the ovaries, or indirectly 
following surgical treatments which can lead to tubal ad-
hesions. There are a number of data about pregnancy out-
comes in young women with CD [4]. However, the results of 
the studies investigating fertility and fecundity in women 
with CD are controversial [5, 6]. Some authors advocate 
a relationship between CD and subfertility [5], while others 
report the same rate of infertility in these patients with that 
of the general population [6, 7].
Ovarian reserve is an indicator of female fertility and 
it can be evaluated with age, follicle stimulating hor-
mone (FSH), luteinizing hormone (LH), estradiol, inhibin B, 
anti-Müllerian hormone (AMH) concentrations, ovarian vol-
ume, antral follicle count (AFC) and ovarian biopsy [8].
In this study, we aimed to evaluate the effects of CD on 
ovarian reserve, and to demonstrate CD’s effect on ovar-
ian ageing by comparing serum AMH, steroids, and gon-
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adotropin levels of female CD patients with the results of 
healthy, and fertile reference population.
MATERIAL AND METHODS 
This prospective case-controlled study was conducted at 
a tertiary referral center in Istanbul province between March 
2019 and August 2019. The study protocol was approved 
by the institution’s Ethics Committee (KAEK/2019.03.40) and 
registered to ClinicalTrials.gov (NCT03897400). According to 
the G-Power analysis, the number of subjects in the study 
group was 50 with 5% error and 80% power. Ninety-five 
patients were recruited to the control group with a case 
control ratio of 1:2.
After receiving ethics approval, 62 female patients, aged 
between 18–40 years, diagnosed with CD who were con-
sulted to our outpatient clinic for gynecological examination 
and who gave written informed consent were included in 
the study. Inclusion criteria were as follows: regular men-
strual periods, no gynecological pathologies detected by 
gynecological or ultrasound examination, and no history 
of infertility. Tweleve CD patients aged over 40 years, who 
had previously undergone ovarian resection, who had 
polycystic ovary syndrome, renal failure (serum creatinine 
levels > 1.2 mg/dL), suspected malignancy, hereditary or 
acquired hematologic disease, who were pregnant or during 
lactation period, who had severe comorbid chronic diseases, 
abnormal thyroid function tests, known serious psychologi-
cal problems or alcohol abuse were excluded from the study. 
In addition, women with first degree relatives diagnosed 
with inflammatory bowel disease (IBD), with positive surgi-
cal histories and currently under medical treatment were 
excluded from the study. The control group consisted of 
women without any known disease and blood transfusion. 
Finally the study included 50 women of reproductive 
age with the diagnosis of CD confirmed with endoscopic, 
radiologic and histopathological findings, and a volunteer 
group of 95 healthy women as the control group. Demo-
graphic features, history of surgical and medical treatments, 
gravidity, parity, menstrual cycle, history of smoking, age of 
CD diagnosis, duration of CD, history of CD related surgery 
and medication were recorded. Body weight and height 
were measured in all women using electronic digital scales 
and light clothes, and body mass index (BMI) was calculated. 
During the early follicular phase (day 3 of the men-
strual cycle) early morning venous blood samples were 
collected in lithium-heparin tubes to determine AMH and 
hormone levels. AMH levels were determined in batches 
using enzyme-linked immunosorbent assay (ELISA) (Ansh 
Labs, Webster, USA). AMH correlates with AFC with a sensi-
tive measurement range of 0.405–6.96 ng/mL [9]. In addi-
tion, serum acute phase reactants (human C reactive protein 
(CRP), erythrocyte sedimentation rate (ESR), platelet count 
and albumin) were measured in all participants.
The Crohn’s Disease Activity Index (CDAI) is used to 
evaluate disease severity. A score ranging from 0 to over 
600 is given to the patients according to their symptoms 
which they record in a diary for seven days along with other 
measurements such as the patient’s weight, CDAI, range 
of bowel involvement and drug use. Patients with a CDAI 
score of < 150 were considered to be in remission, while 
patients with scores higher than 150 were accepted to have 
active disease. All patients received a transvaginal ultrasono-
graphic (TVUS) examination with a 8.5 MHz transvaginal 
transducer (ATL 5000 HDI, Philips, Netherlands) performed 
by a trained physician for the measurements of AFC and 
ovarian volume. AFC was calculated by counting the fol-
licles of 2–10 mm diameter in both ovaries with a standard 
systemic approach. Ovarian volume was calcuted using 
the following formula: Length (L) × Width (W) × Thickness 
(T) × 0.523 [10]. 
Statistical analysis was performed with SPSS Statistics 
v. 20 for Macintosh package software. Normality of the con-
tinuous variables was tested using Kolmogorov-Smirnov test. 
Continuous variables are expressed as mean ± standard de-
viation and nominal variables as number of cases (n) and 
percentage (%). Significance of the differences between 
the groups in terms of the mean values was studied using 
Student’s t test. Nominal valuables were evaluated using 
Chi-square test. Correlation between CDAI and serum AMH 
levels in CD patients was investigated with Pearson’s correla-
tion analysis. A p value of < 0.05 was considered statistically 
significant.
RESULTS 
A total of 157 women matched for demographic features 
including age, gender and BMI were included in the study. 
Among these, 12 CD patients were excluded according to 
the exclusion criteria. The groups consisted of 50 CD patients 
and 95 healthy control subjects. Clinical and demographic 
data of CD patients and healthy controls are shown in Ta-
ble 1. Median follow-up duration was 68 months for CD 
patients. Median CDAI was 128 in these patients. 
Among acute phase reactants, ESR was significantly 
higher in CD patients compared to the healthy controls 
(p < 0.05). There were no significant differences between 
either group in terms of albumin levels, CRP and leukocyte 
counts (p > 0.05). Both groups were statistically similar in 
terms of estradiol (E2), FSH, LH, prolactin (PRL), hemoglo-
bin (g/dL), platelet count (× 103), ferritin (ug/L), creatinine 
(mg/dl) levels. Results of the serum AMH levels, ovarian vol-
umes, and AFC are given in Table 2. Serum AMH levels were 
significantly lower in CD patients (p < 0.05) (Tab. 3).
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Table 1. Demographic ve clinical characteristics of the crohn disease patients and controls
Variables CD patients(n: 50)
Control group
(n: 95) p value
Age [years]* 29.6 ± 6.2 30.6 ± 6.4 0.239
BMI [kg/m2]* 26.5 ± 5.6 25.5 ± 5.3 0.517
Gravidity [n]* 1.6 ± 1.4 1.5 ± 1.1 0.198
Parity [n]* 1.3 ± 1.1 1.2 ± 0.9 0.543
Abortions [n]* 0.1 ± 0.07 0.1 ± 0.05 0.659
Alive [n]* 1.2 ± 0.3 1.1 ± 0.2 0.987
Age at CD onset [years]* 29.6 ± 6.2 – –
Age at CD diagnosis [years]* 21.3 ± 5.1 – –
Disease duration [years]* 5.3 ± 4.1 – –


















*Student’s t- test; ** Chi-square test; CD — crohn disease; BMI — body mass index; Values are presented as mean (standard deviation) for continuous variables and number 
(percent) for categorical variables
Table 2. Anti-Müllerian hormone levels, ovarian volumes, and antral follicle numbers of the groups
Variables CD patients(n: 50)
Control group
(n: 95) p value
AMH [pg/mL, Mean ± SD] 2.1 ± 0.8 3.3 ± 0.9 0.001
Right ovarian volume [cm3] 7.1 ± 4.3 8.8 ± 5.2 0.001
Left ovarian volume [cm3] 7.2 ± 4.1 8.7 ± 4.3 0.002
Right ovarian AFC [n] 4.1 ± 2.1 5.8 ± 2.3 0.002
Left ovarian AFC [n] 3.2 ± 0.8 5.3 ± 2.9 0.001
CD — Crohn disease; SD — standard deviation; AMH — Anti-Müllerian hormone (pg/mL); AFC — antral follicle count
Table 3. Comparison of serum anti-Müllerian hormone levels between crohn disease (CD) patients and controls and various subgroups of CD 
patients
Serum AMH levels [ng/mL] p value
All participants CD patients (n = 50)Controls (n = 95)
2.1 ± 0.8
3.3 ± 0.9 0.001
Disease activity Active CD (n = 21)In-remission (n = 29)
2.1 ± 0.6
2.6 ± 0.8 0.002
Disease duration Less than 5 years (n = 23)More than 5 years (n = 27)
2.7 ± 0.6
2.2 ± 0.4 0.000
History of CD- related surgery Yes (n = 8)No (n = 42)
2.3 ± 0.7
2.5 ± 0.8 0.237
History of medical treatment Yes (n = 40)No (n = 10)
2.6 ± 0.4
2.4 ± 0.8 0.904
CD — crohn disease; AMH — Anti-Müllerian hormone (pg/mL)
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When CD patients were divided into groups according 
to CDAI results; 21 (42%) CD patients were evaluated as 
having active disease and 29 (48%) as in remission. Serum 
AMH levels were significantly lower in CD patients with 
active disease compared to those in remission (p < 0.05). 
Only 8 (16%) CD patients had a history of surgical treat-
ment. Among these, 3 underwent ileal, 2 colonic and 3 il-
eocolonic operations. There was no significant difference 
between these patients and CD patients without a history of 
resection in terms of serum AMH levels (p = 0.237) (Tab. 3). 
Serum AMH levels were lower in smoker CD patients com-
pared to non-smoker CD patients, but the difference was 
not significant (p > 0.05). Among CD patients; 12 received 
azathioprine, 8 received methotrexate, and 20 were treated 
only by infliximab in monotherapy. None of the patients 
received corticosteroids or 5-ASA (5-aminosalicylic acid) 
(Tab. 3). There was no significant difference between the 
patients who received medical therapy and those who did 
not receive in terms of serum AMH levels (p > 0.05).
We performed a correlation analysis between CDAI 
scores and serum AMH levels, disease duration, and ovar-
ian volume. There was a significant negative correlation be-
tween CDAI and serum AMH levels in CD patients (r = –0.317, 
p < 0.001). Again, there was a significant negative correlation 
between disease duration and serum AHM levels in CD 
patients (r = –0.618, p = 0.000). A significant positive cor-
relation was observed between ovarian volume and serum 
AMH levels in CD patients (r = 0.243, p = 0.001).
DISCUSSION 
Gynecological diseases are common in women with CD. 
Therefore, abdominopelvic pain, menstrual irregularities, 
pelvic inflammatory diseases may be related to gynecologi-
cal pathologies such as endometriosis or ovarian patholo-
gies. This may interfere with earlier diagnosis of inflamma-
tory bowel disease due to similar symptoms [5, 11, 12]. 
Women with CD in general are in their reproductive ages 
with a fertility wish. Therefore, they are concerned about 
the harmful effects of the disease on their fertility potential. 
CD has an inflammatory effect on the fallopian tubes and 
ovaries especially during the active phase of the disease 
leading to decreased fertility [5, 6, 12, 13]. AMH seems 
an early, reliable and direct indicator of decreased ovar-
ian function. In IVF studies, a serum AMH level > 1.32 ng/mL 
indicated a good ovarian reserve, while a serum AMH 
level < 1.32 ng/mL has been accepted as an indicator of 
decreased ovarian pool [14]. Therefore, serum AMH levels 
can be used in the evaluation of ovarian reserve [15]. In the 
first study evaluating ovarian reserve using AMH levels, it 
was demonstrated that female CD patients of 30–40 years of 
age had significantly lower AMH levels compared to healthy 
controls [16]. However, this study was retrospectively de-
signed. To our knowledge our study was the first prospective 
study evaluating ovarian reserve in female CD patients. 
After Dr Crohn’s first report on CD and fertility, who 
thought that fertility was not impaired by CD, following 
reports concluded contrary results [5, 6]. These studies 
demonstrated that fertility rate might be lower in women 
with CD compared to the general European and Austral-
ian populations. The etiology is unclear. However, most 
authors suggested that lower fertility rate in women with 
CD was due to the postponement of conception or lack of 
desire to have a child [17]. The lack of desire for conception 
is based on the heritability of CD, the increased risk of con-
genital abnormalities, and teratogenicity of CD medications. 
This underlines the need for a thorough medical communi-
cation on reproduction with CD patients [2, 18]. Postpone-
ment of conception expose women with CD to age related 
change in ovarian reserve and associated infertility.
Epidemiologic studies have demonstrated that female 
fertility decreseases significantly after 30 years of age espe-
cially due to loss of ovarian follicles [19]. This follicular loss 
is physiological in some women, although it can be acceler-
ated, resulting in premature ovarian reserve changes [16]. 
In a recent study, age older than 25 years and an active CD 
were both found to be independently associated with low 
ovarian reserve. Currently AMH is considered as the most 
accurate marker in the evaluation of ovarian reserve. In the 
above-mentioned study, decreased AMH levels i CD patients 
older than 25 years of age were reported. On the other hand 
serum AMH levels of patients younger than 25 were similar 
to that of the controls [20]. 
It has been demonstrated that the levels of serum AHM 
secreted by the antral follicles reflect ovarian follicle pool, 
and can be used as one of the hormonal markers associated 
with ovarian reserve in the diagnosis of ovarian insufficiency 
[21]. There is a lifelong decrease in the number and quality 
of oocytes in normal women [19]. AMH can be successfully 
used in order to evaluate damage to the ovary caused by 
pathologies or therapeutic agents [22]. It is possible to use 
AMH for the evaluation of fertility potential in women with 
CD who are at a higher risk, similarly as used among the 
healthy population [16, 23]. In our study, we discussed the 
effects of AMH levels on fertility potential in women with CD.
In a study by Senates et al. [23], CD patients were 
divided into two groups according to their disease sta-
tus. When these groups were compared with each other, 
serum AMH levels were found to be significantly lower in 
patients with active CD. The mean serum AMH level was 
reported as 0.33 ± 0.25 ng/mL, which was lower than the ac-
cepted cut-off value (0.5 ng/mL) for normal ovarian reserve. 
This result supports other studies showing that fertility is 
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very low in female CD patients even in the absence of any 
structural pathology in the genital system [23]. In our study, 
we observed differences in the medical histories, various 
exacerbation frequencies and medication protocols of CD 
patients. This enabled us to evaluate the study population 
also in terms of inflammation and disease activity. Serum 
AMH levels were significantly lower in patients with active 
disease.
Intestinal and extra-intestinal complications in CD pa-
tients tend to increase as the duration of the disease is 
prolonged [24]. We also evaluated serum AMH levels on the 
basis of disease duration. When CD patients were divided 
into groups according to disease duration and AMH levels; 
serum AMH levels were found to be higher in patients with 
a disease of duration less than five years.
Furthermore, pelvic surgery may cause damage to re-
productive organs, namely ovaries and tubas especially 
following ileal pouch-anal anastomosis [25]. Previous studies 
have suggested an association between surgical interven-
tion and decreased fertility in women with CD [26]. In the 
present study, no significant difference was found in serum 
AMH levels between women operated due to CD and those 
without a history of surgery.
In our study, along with the other factors that may dam-
age reproduction performance, smoking status was also 
recorded in women with CD. In a study by Van der Heide et 
al. [25], patients known to have CD were mostly smokers. 
In that study, smoking in CD patients was associated with 
longer exacerbation periods, more complications, more 
need for steroids and postoperative relapse [27]. Detrimental 
effects of tobacco on ovarian physiology has been subject 
to debate for a long time, and some newer studies have 
demonstrated decreased ovarian reserve in smokers [28]. 
In our study, AMH levels were higher in non-smoker CD 
patients than in smoker ones, but the difference between 
smokers and non-smokers was not statistically significant.
Although our study has the power for evaluating se-
rum AMH levels between patient and control groups, our 
relatively small number of patients could limit generaliza-
tion of our results. Since this study was conducted with 
Turkish-origin individuals, it could be insufficient in evalu-
ation of individuals from different ethnic origins. One of the 
limitations of our study is; Even if the number of patients 
receiving immunosuppressive agents is low, it is not possible 
to distinguish whether the cause of low ovarian reserve is 
caused by Crohn disease or medical treatment used for the 
disease. However, being the first prospective study about 
ovarian reserve among Crohn’s disease patients, and using 
additional parameters such as AFC, ovarian volume and FSH 
in addition to AHM are strengths of our study. 
CONCLUSIONS
This study demostrated that CD causes a significant 
decrease in serum AMH levels of women within the repro-
ductive ages compared to healthy women. This effect is 
most prominent in active disease periods. In the light of 
these data, we believe that CD patients’ awareness of their 
reproductive potential could be increased by ovarian re-
serve evaluation to be performed in an early period, and 
making conception plans in this direction could be helpful 
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